Shares of Viking Therapeutics (NASDAQ: VKTX), a clinical-stage drugmaker working on metabolic treatments, have tripled in value this year. Despite the huge run-up, analysts who follow the company ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback